All In Biotech

Drug Trial Radar · NCT00954629

A Study of the Efficacy and Safety of 2PX in Patients With Pain Due to Osteoarthritis of the Knee

A 26 Week Placebo-controlled, Randomised, Double-blind, Parallel Group Study of the Efficacy and Safety of 2PX (Topical Strontium Chloride Hexahydrate) in Patients With Pain Due to Osteoarthritis of the Knee

Last checked: Nov 19, 2026Latest source record: Mar 24, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

300

Planned (sponsor's estimate)

Start

Jun 2009

Primary completion

May 2010

Study completion May 2010

Sponsor

Lead sponsor
Smerud Medical Research International ASAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
SantoSolve AS
First posted
Aug 7, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to demonstrate the superiority of topically administered 2PX versus placebo (vehicle) control in terms of reduction in pain intensity and physical function.

Conditions

  • Pain
  • Osteoarthritis

Interventions

  • strontium chloride hexahydrateDrug

    Topical solution to be applied twice daily for 26 weeks. Dosage of up till 4 ml per application.

  • PlaceboDrug

    Topical solution to be applied twice daily for 26 weeks. Dosage up till 4ml per application.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The difference between the active and placebo group in the change from Baseline to the assessment after 26 weeks of treatment in the actual WOMAC Osteoarthritis Index LK 3.1 subscale score for pain and physical function.Time frame: 26 weeks

Locations

15 sites in 4 countries. Site status is shown where the registry gives one.

  • Site in Helsinki

    Helsinki, Finland · Completed

  • Site at Kuopio

    Kuopio, Finland · Completed

  • Site in Turku

    Turku, Finland · Completed

  • Site in Bialystok

    Bialystok, Poland · Completed

  • Site in Kraków

    Krakow, Poland · Completed

  • Site in Warszawa

    Warsaw, Poland · Completed

  • Site in St-Petersburg

    Saint Petersburg, Russia · Completed

  • Site in St-Petersburg

    Saint Petersburg, Russia · Recruiting

  • Site in Blackpool

    Blackpool, United Kingdom · Completed

  • Site in Bolton

    Bolton, United Kingdom · Completed

  • Site in Bradford

    Bradford, United Kingdom · Completed

  • Site in Manchester

    Manchester, United Kingdom · Completed

  • Site at Cheadle Hulme

    Stockport, United Kingdom · Completed

  • Site at Heald Green

    Stockport, United Kingdom · Completed

  • Site at Heaton Moor

    Stockport, United Kingdom · Completed

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.